Skip to main content

casdozokitug

Generic: Casdozokitug·Code: CHS-388, SRF388

casdozokitug: developed by 1 company · 2 clinical trials tracked.

casdozokitug evidence translation

What we can confirm

What it means

Source-backed records connect casdozokitug to CHRS; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could casdozokitug → CHRS affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
Coherus Oncology, Inc. (CHRS)
Hepatocellular Carcinoma
Phase 2
Clinical Trials (2)

A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

NCT06679985·Phase 2·CHRS
Active, not recruiting

Primary endpoint: Number of Participants with Treatment-emergent Adverse Events (TEAEs)

InterventionalRandomizedopen72 targetStarted 2024-12Completion 2027-0944 sites · Australia, Canada, Hong Kong, Singapore…Coherus Oncology, Inc.

A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

NCT04374877·Phase 1·CHRS
Completed

Primary endpoint: [Part A] Dose Limiting Toxicity (DLT)

Interventionalopen145 enrolledStarted 2020-04Completion 2025-0623 sites · Singapore, South Korea, United StatesCoherus Oncology, Inc.

Frequently asked questions

Who is developing casdozokitug?

casdozokitug is being developed by Coherus Oncology, Inc..

How many clinical trials involve casdozokitug?

BioSniper tracks 2 clinical trials involving casdozokitug.